UBS raised the firm’s price target on Gentex (GNTX) to $28 from $23 and keeps a Neutral rating on the shares. The firm walked away from the Q2 earnings report more positive, with gross margin upside and the profitability profile of VOXX not being as bad as feared, but thinks consensus 2026 numbers may move up mid to high single digits and second half gross margins should step down, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNTX: